Shah Tushar
Known title: CMO and Head of R&DCIK: 0001487632
Associated companies
Transaction History
| LQDA | ▼ Sell | Tax Withholding | 11,882 | $58K | 11/12/2021 | View on chart |
| LQDA | ▼ Sell | Tax Withholding | 487 | $2K | 11/12/2021 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 51,250 | — | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.